Replies to post #17513 on Biotech Values

[io_io]

first-line and off-label:

Am curious about this - is it perfectly logical that Erbitux be second-line (to chemo I presume), or is this a consequence of the clinical trial process in that it is difficult to displace the SoC due to ethical concerns..........

I mean it's not that Erbitux is 2nd-best to anything in CRC ?